MRG003 has already shown encouraging outcomes, following results of another phase I trial, when used in the treatment of patients with EGFR positive refractory advanced squamous cell carcinomas of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), and colorectal cancer (CRC) [102]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.